<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713178</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-326</org_study_id>
    <nct_id>NCT02713178</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pacira Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pacira Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in
      approximately 300 adult subjects undergoing primary unilateral TKA under general or spinal
      anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On Day 0, eligible subjects will be randomized in a 1:1:1 ratio to receive a single dose of
      either EXPAREL 133 mg in 10 mL expanded in volume with 10 mL of normal saline for a total
      volume of 20 mL (Group 1); EXPAREL 266 mg in 20 mL (Group 2); or placebo 20 mL (Group 3).
      Study drug (EXPAREL or placebo) will be administered in a blinded manner via an ultrasound
      guided single-dose femoral nerve block at least 1 hour prior to surgery. Prior to placement
      of the prosthesis, 8 mL of bupivacaine hydrochloride (HCl) (0.5%) diluted with 8 mL of normal
      saline will be administered by the surgeon as a periarticular infiltration to the posterior
      capsule (8 mL medially and 8 mL laterally).

      Postsurgical assessments will include pain intensity scores using a 10-cm visual analog scale
      (VAS); total postsurgical opioid consumption; overall benefit of analgesia score (OBAS)
      questionnaire; subject satisfaction with overall analgesia using a 5-point Likert scale;
      neurological assessment; sensory function assessment; motor function assessment; the study
      physical therapy assessments (ie, timed walk, timed up and go, and stair climbing tests);
      discharge readiness; unscheduled phone calls or office visits related to pain; 12-lead ECGs;
      vital sign measurements; and clinical laboratory tests. Adverse events will be recorded from
      the time the informed consent form (ICF) is signed through postsurgical Day 29.

      Follow-up visits will be scheduled for all subjects on postsurgical Days 6 and 10. A
      follow-up phone call will be made on postsurgical Day 29.

      Pharmacokinetic (PK) parameters will be estimated from plasma bupivacaine measurements using
      non-compartmental analysis based on the sampling schedule of baseline (prior to the nerve
      block) through postsurgical Day 10.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of the VAS pain intensity scores</measure>
    <time_frame>Through 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total postsurgical opioid consumption (in IV morphine equivalents)</measure>
    <time_frame>Through 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of opioid-free subjects</measure>
    <time_frame>Through 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid rescue</measure>
    <time_frame>Through 72 hours</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse events and serious adverse events</measure>
    <time_frame>Through postsurgical Day 29</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>EXPAREL 133 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 133 mg (10 mL) EXPAREL (bupivacaine liposome injectable suspension) expanded in volume with 10 mL of normal saline for a total volume of 20 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPAREL 266 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of 266 mg (20 mL) EXPAREL (bupivacaine liposome injectable suspension).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline (20 mL).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupivacaine liposome injectable suspension</intervention_name>
    <description>bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL</description>
    <arm_group_label>EXPAREL 133 mg</arm_group_label>
    <arm_group_label>EXPAREL 266 mg</arm_group_label>
    <other_name>EXPAREL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, at least 18 years of age at screening.

          2. Scheduled to undergo primary unilateral TKA under general or spinal anesthesia.

          3. American Society of Anesthesiologists (ASA) physical status 1, 2, or 3.

          4. Female subject must be surgically sterile; or at least 2 years postmenopausal; or have
             a monogamous partner who is surgically sterile; or practicing double-barrier
             contraception; or practicing abstinence (must agree to use double-barrier
             contraception in the event of sexual activity); or using an insertable, injectable,
             transdermal, or combination oral contraceptive approved by the FDA for greater than 2
             months prior to screening and commit to the use of an acceptable form of birth control
             for the duration of the study and for 30 days after completion of the study.

          5. Able to demonstrate sensory function by exhibiting sensitivity to cold, pinprick, and
             light touch.

          6. Able to provide informed consent, adhere to the study visit schedule, and complete all
             study assessments.

        Exclusion Criteria:

          1. Currently pregnant, nursing, or planning to become pregnant during the study or within
             1 month after study drug administration.

          2. Planned concurrent surgical procedure (e.g., bilateral TKA).

          3. Concurrent painful physical condition that may require analgesic treatment (such as an
             NSAID or opioid) in the postsurgical period for pain that is not strictly related to
             the knee surgery and which may confound the postsurgical assessments (e.g.,
             significant pain from other joints including the non-index knee joint, chronic
             neuropathic pain, concurrent or prior contralateral TKA, concurrent foot surgery).

          4. Previous open knee surgery on the knee being considered for TKA. Prior arthroscopy is
             permitted.

          5. History of hypersensitivity or idiosyncratic reaction to amide-type local anesthetics.

          6. Contraindication to any one of the following: bupivacaine, oxycodone, morphine, or
             hydromorphone.

          7. Use of any of the following medications within the times specified before surgery:
             long-acting opioid medication or NSAIDs (except for low-dose aspirin used for
             cardioprotection) within 3 days, or any opioid medication within 24 hours.

          8. Initiation of treatment with any of the following medications within 1 month of study
             drug administration or if the medication(s) are being given to control pain: selective
             serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors
             (SNRIs), gabapentin, pregabalin (Lyrica®), or duloxetine (Cymbalta®). If a subject is
             taking one of these medications for a reason other than pain control, he or she must
             be on a stable dose for at least 1 month prior to study drug administration.

          9. Current use of systemic glucocorticosteroids within 1 month of enrollment in this
             study.

         10. Use of dexmedetomidine HCl (Precedex®) within 3 days of study drug administration.

         11. History of impaired kidney function, poorly controlled chronic respiratory disease,
             rheumatoid arthritis, coagulopathy, or loss of sensation in extremities.

         12. Impaired kidney function (e.g., serum creatinine level &gt;2 mg/dL [176.8 µmol/L] or
             blood urea nitrogen level &gt;50 mg/dL [17.9 mmol/L]) or impaired liver function (e.g.,
             serum aspartate aminotransferase [AST] level &gt;3 times the upper limit of normal [ULN]
             or serum alanine aminotransferase [ALT] level &gt;3 times the ULN.)

         13. Uncontrolled anxiety, psychiatric, or neurological disorder that might interfere with
             study assessments.

         14. Any chronic neuromuscular deficit effecting the peripheral nerves or muscles of the
             surgical extremity.

         15. Any chronic condition or disease that would compromise neurological or vascular
             assessments.

         16. Malignancy in the last 2 years, with the exception of non-metastatic basal cell or
             squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.

         17. Suspected or known history of drug or alcohol abuse within the previous year.

         18. Body weight &lt;50 kg (110 pounds) or a body mass index &gt;44 kg/m2.

         19. Previous participation in an EXPAREL study.

         20. Administration of an investigational drug within 30 days or 5 elimination half-lives
             of such investigational drug, whichever is longer, prior to study drug administration,
             or planned administration of another investigational product or procedure during the
             subject's participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James B Jones, MD, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Pacira Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hassan Danesi</last_name>
    <phone>973-451-4047</phone>
    <email>Hassan.Danesi@pacira.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brookwood Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Smith</last_name>
      <phone>205-271-6507</phone>
      <email>lsmith@aoc-research.com</email>
    </contact>
    <investigator>
      <last_name>Robert Sorrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Research Group, Inc</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Hess</last_name>
      <phone>251-410-3705</phone>
      <email>lhess@horizonresearch.us</email>
    </contact>
    <investigator>
      <last_name>Robert Calin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Keller Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>Alabama</state>
        <zip>35660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy Puckett</last_name>
      <phone>256-386-4001</phone>
      <email>puckchristy@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Timothy Melson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Metro Orthopedics</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hannah Olds</last_name>
      <phone>303-789-3000</phone>
      <email>hannah.olds@colorado.edu</email>
    </contact>
    <investigator>
      <last_name>John Schwappach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shrock Orthopedic Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalie Shrock</last_name>
      <phone>954-626-3743</phone>
      <email>natalie@shrockresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Shrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jackson Memorial Hospital/University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margarita Nieto Moreno</last_name>
      <email>m.nieto@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alessandro Colantuono</last_name>
      <phone>305-585-7677</phone>
    </contact_backup>
    <investigator>
      <last_name>Keith Candiotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pensacola Research Associates</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Satterwhite</last_name>
      <phone>850-477-7900</phone>
      <phone_ext>2003</phone_ext>
      <email>a.satterwhite@pensacolaresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Donna Lawson</last_name>
      <phone>850-477-7900</phone>
      <phone_ext>2105</phone_ext>
      <email>d.lawson@pensacolaresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>E J Dabezies, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Bhandari</last_name>
      <phone>617-732-9816</phone>
      <email>abhandari1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Srdjan Nedeljkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashish Bhandari</last_name>
      <phone>617-732-9816</phone>
      <email>abhandari1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Srdjan Nedeljkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook Medicine</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabeen Rizwan</last_name>
      <phone>631-638-1214</phone>
      <email>sabeen.rizwan@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Syed Azim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Singh Nair</last_name>
      <phone>718-920-5932</phone>
      <email>sinair@montefiore.edu</email>
    </contact>
    <investigator>
      <last_name>Boleslav Kosharskyy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Raleigh-Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Pucci</last_name>
      <email>alicia.pucci@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Visaya</last_name>
      <phone>919-668-2437</phone>
      <email>renee.visaya@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffery Gadsden, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Regional Medical Center</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Boyer</last_name>
      <phone>724-349-0520</phone>
      <email>sboyer@antria.org</email>
    </contact>
    <investigator>
      <last_name>David Bizousky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lessin, BA RN CCRC</last_name>
      <phone>215-955-5804</phone>
      <email>jennifer.lessin@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robert Machinski</last_name>
      <phone>610-348-3537</phone>
      <email>robert.machinski@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene R Viscusi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hermann Drive Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Howard</last_name>
      <phone>281-770-5752</phone>
      <email>lauren@minkowitzmd.com</email>
    </contact>
    <investigator>
      <last_name>David Leiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westside Surgical Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Bailon</last_name>
      <phone>713-480-3028</phone>
      <email>sandra@minkowitzmd.com</email>
    </contact>
    <contact_backup>
      <last_name>Pam Lindley</last_name>
      <phone>832-567-2273</phone>
      <email>pam@minkowitzmd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Harold Minkowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southampton Orthopaedics Sports Medicine</name>
      <address>
        <city>Franklin</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vishaili Patel</last_name>
      <phone>267-968-5239</phone>
      <email>research@summitcr.com</email>
    </contact>
    <investigator>
      <last_name>Manish Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Golebiewski</last_name>
      <phone>491633123175</phone>
      <email>monica.golebiewski84@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marijke Cipers</last_name>
      <email>marijke.cipers@zol.be</email>
    </contact_backup>
    <investigator>
      <last_name>Sam Van Boxstael, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siska Bjørn</last_name>
      <phone>4560651087</phone>
      <email>siska.bjoern@post.au.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas Fichtner Bendtsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionshospital Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Rolighed Larsen</last_name>
      <phone>4530512492</phone>
      <email>jens.rolighed@clin.au.dk</email>
    </contact>
    <investigator>
      <last_name>Jens Rolighed Larsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

